The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).
J. P. Bleuse
No relevant relationships to disclose
H. J. Meulenbeld
No relevant relationships to disclose
E. M. Vinci
No relevant relationships to disclose
E. Raymond
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; Novartis; Pfizer
G. Vitali
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose
L. Dogliotti
No relevant relationships to disclose
R. Berardi
No relevant relationships to disclose
F. Cappuzzo
No relevant relationships to disclose
S. T. Tagawa
No relevant relationships to disclose
C. N. Sternberg
Honoraria - Amgen; Astellas Pharma; Johnson & Johnson; Sanofi
Research Funding - Cougar Biotechnology
M. G. Jannuzzo
Employment or Leadership Position - Nerviano
M. Mariani
Employment or Leadership Position - Nerviano
A. Petroccione
Employment or Leadership Position - Nerviano
R. De Wit
No relevant relationships to disclose